A review of the neutralizing antibody that was studied in a phase 2/3 trial in outpatients with mild to moderate infections of COVID-19.
MONICA V. MAHONEY, PHARMD, BCPS AQ-ID, BCIDP*
Advertisement
Articles by MONICA V. MAHONEY, PHARMD, BCPS AQ-ID, BCIDP*
Contagion® radio is here to bring joy with every new antibiotic alert!
Fosfomycin is an attractive potential option because it does not cross-react with other antimicrobials, making it a good choice in patients with extensive drug allergies.
Advertisement
Latest Updated Articles
Shoutout to the Stewards: Holiday EditionPublished: December 23rd 2019 | Updated:
- Postulates About the Prostate: Fosfomycin for Chronic Bacterial Prostatitis
Published: August 5th 2019 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
CDC ACIP Delays Votes on Hepatitis B Birth Dose Until Tomorrow
2
Early 2025 Influenza Vaccination Trends Following Prior Season and H3N2 Start
3
Call to Consider Off-Label COVID-19 Vaccination for Children
4
HIV Drug Resistance Declines in the Modern ART Era
5
